Home > Boards > US Listed > Biotechs > METACRINE (MTCR)

MTCR starts phase-2a for MET642—the follow-on FXR agonist

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 751
Posts 115,973
Boards Moderated 12
Alias Born 09/05/02
160x600 placeholder
Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH GlobeNewswire Inc. - 6/2/2021 8:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2021 4:31:05 PM
Metacrine to Present at 2021 Jefferies Healthcare Conference GlobeNewswire Inc. - 5/26/2021 8:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 7:03:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 7:01:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 7:00:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:59:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:58:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:56:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:56:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/25/2021 6:55:23 PM
Metracrine rises 10.27% after hours as CMO and CEO acquires shares Seeking Alpha - 5/21/2021 5:30:44 AM
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meet... GlobeNewswire Inc. - 5/19/2021 8:05:00 AM
Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis GlobeNewswire Inc. - 5/18/2021 8:05:00 AM
Metacrine reports Q1 results Seeking Alpha - 5/13/2021 5:31:36 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 4:18:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/13/2021 4:11:33 PM
Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results GlobeNewswire Inc. - 5/13/2021 4:05:00 PM
Metacrine to Present at 2021 RBC Global Healthcare Conference GlobeNewswire Inc. - 5/11/2021 8:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 6:37:36 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/9/2021 4:11:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/5/2021 4:11:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/5/2021 4:10:54 PM
Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors GlobeNewswire Inc. - 4/5/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/18/2021 4:53:25 PM
DewDiligence Member Level  Tuesday, 03/09/21 09:39:35 AM
Re: DewDiligence post# 8
Post # of 11 
MTCR starts phase-2a for MET642—the follow-on FXR agonist to MET409:

https://finance.yahoo.com/news/metacrine-initiates-phase-2a-trial-113000073.html
Quote:
The Phase 2a clinical trial is a 16-week, randomized, placebo-controlled, multi-center trial evaluating the safety, tolerability and pharmacological activity (as measured by liver fat reduction) of MET642 (3 mg and 6 mg) vs placebo. An interim analysis is planned in the fourth quarter of 2021, after approximately 60 patients have completed 16 weeks of treatment. Topline trial results of up to 180 patients are expected to be reported in the first half of 2022.

See #msg-162210410 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences